x 

0 Activities
0 Activities
    • No Saved Activities
Page 2 of 2
Results 151 - 243 of 243
No image set
Treatment of Ph+ Relapsed/Refractory ALL
No image set
Treatment of Ph- Relapsed/Refractory ALL
9157-0003-slide263x149
NTM-LD Daignosis and Management - Slide Deck
No image set
Identification of Relapsed ALL
No image set
ILD Patient Case Library: IPF, PF-ILD, SSc-ILD, and Post COVID-19
9089_nsclc_titleslide
TARGET for NSCLC: Genomic Pathways and Use of EGFR Therapies
No image set
PAH: Risk Reduction Strategies Using Single and Combination Therapies
No image set
Ensuring Effective Care Transitions in Beta Thalassemia
No image set
Improved Patient Outcomes in PAH
9101-chest
IPF Management and Antifibrotic Therapy
No image set
A Collaborative Approach to IPF Management
No image set
Practical Solutions to SSc-ILD Treatment
No image set
Post COVID-19 and Patients With and Without Pre-existing ILD
No image set
Reversing DOACS: Providing Answers to What, Where and How
No image set
Reversing DOACS: Recording from Live Session held on July 18, 2021
No image set
Conquer the Clot: Addressing VTE in Your Patients with Cancer
9076-0001-263x149
Healthcare Disparities in African Americans With Myeloma
No image set
Perioperative Nutrition and Wound Healing
No image set
Special Considerations for Nutrition for the Elderly
No image set
Diabetes & Nutrition
No image set
Itching for Relief: Atopic Dermatitis Management Considerations for PAs and NPs
No image set
Exploring the Evidence, the Reality, and the Potential of CGM
No image set
COVID-19 Acute and Long-term Lung Injury
No image set
COVID-19 and ARDS: East Coast Experiences
No image set
Practical Questions in the Diagnosis and Management of Patients With MAC
No image set
COVID-19 and ARDS: West Coast Experiences
9165 product
Utilizing ACIP's Updated Pneumococcal Recommendations - Rapid Recap
No image set
Advances in Multiple Sclerosis (AIMS) Primer: 3rd Edition
No image set
A Practical Guide to Rehabilitation in Multiple Sclerosis: 2nd Edition
No image set
Palliative Embolization
No image set
Vertebroplasty and Vertebral Augmentation for Spine Metastases or Pathologic Fractures
No image set
Effective Communication With Your Patient and Family
No image set
Palliative Ablations of Bone and Soft Tissue Tumors
9840-0004-icon
Acute Exacerbations of IPF
9840-glassberg2
Evaluation and Diagnosis of IPF
9840-glassberg1
Initial Treatment Decisions of IPF
9837-coolidge
What if President Calvin Coolidge Was Your Asthma Patient?
9840-0003
Optimizing Management of IPF
9837-roosevelt
How Would You Manage President Theodore Roosevelt’s Asthma Today?
No image set
Updates in Atopic Dermatitis: The Allergist’s Guide to Optimizing Care - Child
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Addressing Common Barriers to Adherence
Page 2 of 2

Search